Knockout of Trpa1 or blockade of TRPA1‐channel function by the selective antagonist HC‐030031 restores cognition and reduces Aβ plaque deposition and proinflammatory cytokine (IL‐1β, IL‐6, and IL‐4) release in AD mice through the Ca2+‐PP2B/NF‐κB signaling pathway [38]. This evidence concerns the gene TRPA1 and Alzheimer disease.